ReviewMedicines (Basel, Switzerland)2023
Choroidal Melanoma: A Mini Review.
Review in Medicines (Basel, Switzerland), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
12 citing papers in PubMed.
- Stereo-Vision-Inspired Spectral Disparity Learning for Choroidal Tumor Thickness Prediction.Translational vision science & technology · 2026Article
- Article
- Toward Precision Medicine: Gene Therapy Applications in the Management of Uveal Melanoma.Cancer reports (Hoboken, N.J.) · 2025Review
- The Small Choroidal Melanoma: Diagnosis, Treatment Outcomes, and Unending Controversy.Seminars in ophthalmology · 2025Review
- Advances in Positron Emission Tomography/Computed Tomography for Diagnosing and Managing Primary Posterior Uveal Melanoma.Medical science monitor : international medical journal of experimental and clinical research · 2025Review
- Widefield OCT angiography.Progress in retinal and eye research · 2025Review
- An Optimized NGS Workflow Defines Genetically Based Prognostic Categories for Patients with Uveal Melanoma.Biomolecules · 2025Article
- Oncolytic Viruses and Immunotherapy for the Treatment of Uveal Melanoma and Retinoblastoma: The Current Landscape and Novel Advances.Biomedicines · 2025Review
- Artificial intelligence in the diagnosis of uveal melanoma: advances and applications.Experimental biology and medicine (Maywood, N.J.) · 2025Review
- Malignant Transformation of a Choroidal Nevus.Cureus · 2024Article
- Blue Light-Induced Mitochondrial Oxidative Damage Underlay Retinal Pigment Epithelial Cell Apoptosis.International journal of molecular sciences · 2024Article
- Ultrasound-assisted laser therapy for selective removal of melanoma cells.Experimental biology and medicine (Maywood, N.J.) · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Choroidal melanoma is a rare malignant tumour, yet it is the most common primary intra-ocular neoplasm and second on the list of top ten most malignant melanoma sites in the body. Clinical presentation can be non-specific and includes photopsia, floaters, progressive visual field loss, and blurry vision. The tumour is quite often diagnosed clinically during fundus examination; however, the most valued diagnostic tests are A- and B-scan ultrasonography (US). Several factors affect prognosis, including the patient's age, tumour size, histological features, and presence of metastases. Still, with primary treatment and tight surveillance, around 50% of choroidal melanoma patients metastasise.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.